Was treat-and-extend faricimab (Vabysmo, Genentech) an effective means of controlling DME in the YOSEMITE and RHINE studies? New Retina Radio spoke with John Kitchens, MD, whose ASRS presentation reviewed results from a pair of phase 3 studies that assessed, in part, 12- and 16-week dosing intervals of faricimab in patients with DME. 

Also joining us is Michael Allingham, MD, PhD. He shared results from the phase 2b ZETA-1 study, which examined the safety and efficacy of APX3330 (Ocuphire Pharma), an oral medication for DR. What promise might this treatment hold? Tune in to learn more. 

This editorially independent podcast is supported with advertising.

Aflevering-ID: 1000574960745

GUID: 014283e4-11db-11ed-9d35-5301ce5dcf55

Releasedatum: 4-8-2022 06:01:00